Rossari Biotech Limited has completed the sale of its office premises at Kanjurmarg, Mumbai on January 23, 2026. The company notified both BSE and National Stock Exchange of India Limited about the successful completion of this property transaction through a regulatory filing.

Transaction Completion Details

The specialty chemicals company confirmed that the sale transaction was duly completed on January 23, 2026, following its earlier intimation to the stock exchanges. The completion represents the finalization of the property divestment process that was initially disclosed to the exchanges on January 17, 2026.

Regulatory Compliance Framework

The transaction completion was reported under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company referenced compliance with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Corporate Communication

Parul Gupta, Head - Company Secretary & Legal, signed the regulatory filing on behalf of Rossari Biotech Limited. The company stated that all required details pursuant to the listing regulations were previously disclosed in their January 17, 2026 intimation letter. The information has been made available on the company's website at www.rossari.com for stakeholder access.

Company Background

Rossari Biotech Limited operates as an ISO 9001:2015 & 14001:2015 certified company with CIN: L24100MH2009PLC194818. The company maintains its registered office at Rossari House, Golden Oak, LBS Marg, Surya Nagar, Vikhroli (West), Mumbai, along with manufacturing facilities in Silvassa and Bharuch, Gujarat.

Rossari Biotech management has provided an update on supply chain constraints that have been affecting the company's operations. During a recent conference call, the company addressed concerns regarding ethylene oxide availability, which has been impacting production capabilities.

Supply Chain Outlook

The management indicated that the ethylene oxide supply situation, currently acting as a near-term operational constraint, is expected to ease during the current calendar year. This guidance suggests potential relief from the supply bottlenecks that have been affecting the company's production processes.

Operational Impact

Ethylene oxide is a critical raw material for various chemical processes, and supply constraints in this area can significantly impact manufacturing operations. The expected improvement in supply availability could help normalize production schedules and support operational efficiency.

The company's guidance provides clarity on the timeline for potential resolution of these supply chain challenges, which could be important for operational planning and capacity utilization going forward.